Sandra PÃ©rez-Torras

List of Publications by Year
in descending order

22 papers	606 citations	759233 12 h-index	713466 21 g-index
22 all docs	22 docs citations	22 times ranked	1177 citing authors

#	Article	IF	Citations
1	An Escape-Room about Krebs cycle prepared for Chemical Students. International Journal on Engineering, Science and Technology, 2022, 3, 155-164.	0.4	1
2	Dexamethasone-Loaded Lipomers: Development, Characterization, and Skin Biodistribution Studies. Pharmaceutics, 2021, 13, 533.	4.5	7
3	The Physicochemical, Biopharmaceutical, and In Vitro Efficacy Properties of Freeze-Dried Dexamethasone-Loaded Lipomers. Pharmaceutics, 2021, 13, 1322.	4.5	7
4	OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1. Cellular and Molecular Life Sciences, 2021, 78, 7505-7518.	5.4	2
5	FMS-like tyrosine kinase 3 (FLT3) modulates key enzymes of nucleotide metabolism implicated in cytarabine responsiveness in pediatric acute leukemia. Pharmacological Research, 2020, 151, 104556.	7.1	3
6	Deficiency of perforin and hCNT1, a novel inborn error of pyrimidine metabolism, associated with a rapidly developing lethal phenotype due to multi-organ failure. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1182-1191.	3.8	8
7	Emerging Roles of Nucleoside Transporters. Frontiers in Pharmacology, 2018, 9, 606.	3.5	105
8	Who Is Who in Adenosine Transport. Frontiers in Pharmacology, 2018, 9, 627.	3.5	85
9	Intestinal Nucleoside Transporters: Function, Expression, and Regulation. , 2018, 8, 1003-1017.		35
10	Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. Oncotarget, 2017, 8, 90185-90196.	1.8	6
11	Pharmacogenomic analyzis of the responsiveness of gastrointestinal tumor cell lines to drug therapy: A transportome approach. Pharmacological Research, 2016, 113, 364-375.	7.1	4
12	Transportome Profiling Identifies Profound Alterations in Crohnâ€™s Disease Partially Restored by Commensal Bacteria. Journal of Crohn's and Colitis, 2016, 10, 850-859.	1.3	21
13	Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. Journal of Pharmacological Sciences, 2015, 127, 319-325.	2.5	45
14	Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Frontiers in Pharmacology, 2015, 6, 13.	3.5	84
15	Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors. BMC Cancer, 2015, 15, 223.	2.6	16
16	Concentrative nucleoside transporter 1 (hCNT1) promotes phenotypic changes relevant to tumor biology in a translocation-independent manner. Cell Death and Disease, 2013, 4, e648-e648.	6.3	26
17	Role of the Transporter Regulator Protein (RS1) in the Modulation of Concentrative Nucleoside Transporters (CNTs) in Epithelia. Molecular Pharmacology, 2012, 82, 59-67.	2.3	12
18	Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs. BMC Cancer, 2012, 12, 434.	2.6	28

#	Article	IF	Citations
19	New role of the human equilibrative nucleoside transporter 1 (hENT1) in Epithelialâ€toâ€mesenchymal transition in renal tubular cells. Journal of Cellular Physiology, 2012, 227, 1521-1528.	4.1	15
20	Connexin-26 Is a Key Factor Mediating Gemcitabine Bystander Effect. Molecular Cancer Therapeutics, 2011, 10, 505-517.	4.1	33
21	Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening. Cellular Oncology (Dordrecht), 2011, 34, 511-521.	4.4	23
22	Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochemical Pharmacology, 2008, 76, 322-329.	4.4	40